Evolve BioSystems Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 46
Employees
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 11

Evolve BioSystems General Information

Description

Developer of microbiome-based products designed to develop the next generation of products to establish, restore and maintain a healthy gut microbiome. The company's products focus on solving the gut dysbiosis throughout the human life cycle as well as in various animal species, enabling physicians to maintain the healthy gut microbiome in newborn infants with a consumer-directed home use product, and a hospital-based neonatal ICU product.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Other Healthcare Services
Other Healthcare
Primary Office
  • 2121 2nd Street
  • Suite C108
  • Davis, CA 95618
  • United States
+1 (530) 000-0000

Evolve BioSystems Timeline

2017201820192020
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Evolve BioSystems Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Debt - PPP 11-Jun-2020 0000 Completed Generating Revenue
5. Later Stage VC (Series C) 12-Jun-2018 0000 0000 00000 Completed Generating Revenue/Not Profitable
4. Early Stage VC (Series B) 30-May-2017 0000 0000 0000 Completed Generating Revenue/Not Profitable
3. Early Stage VC (Series A) 17-Aug-2015 000 0000 0000 Completed Startup
2. Seed Round 15-Sep-2014 $1M $1M 00.00 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Evolve BioSystems’s complete valuation and funding history, request access »

Evolve BioSystems Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 2,091,709 $0.000100 $0.34 $4.3 $4.8 1x $4.3 14.64%
Seed 725,098 $0.000100 $0.11 $1.32 $1.48 1x $1.32 5.07%
To view Evolve BioSystems’s complete cap table history, request access »

Evolve BioSystems Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of microbiome-based products designed to develop the next generation of products to establish, restore and mai
Biotechnology
Davis, CA
46 As of 2020
0000
000000000 - 0000

00000000

itation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000 000000000
Duarte, CA
000 As of 0000
000.00
0000000000 0 000.00

0000000

um dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
0000000000000
Bedford, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evolve BioSystems Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prolacta Bioscience Venture Capital-Backed Duarte, CA 000 000.00 0000000000 0 000.00
0000000 0000000000 Formerly VC-backed Bedford, MA 00 00000 00000000 00000
00000000 Venture Capital-Backed New York, NY 00 00000 00000000000 00000
00000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
00000 (0000 000000 Venture Capital-Backed Somerville, MA 000 00000 00000000000 00000
You’re viewing 5 of 8 competitors. Get the full list »

Evolve BioSystems Executive Team (12)

Name Title Board Seat Contact Info
Timothy Brown Chief Executive Officer & Board Member
Sandy Argabrite Chief Financial Officer
David Kyle Ph.D Co-Founder , Executive Chairman & Chief Scientific Officer
Samara Freeman Ph.D Co-Founder & Director, Intellectual Property & Regulatory Affairs
Christie Fleming Senior Vice President of Marketing
You’re viewing 5 of 12 executive team members. Get the full list »

Evolve BioSystems Board Members (10)

Name Representing Role Since
David Kyle Ph.D Evolve BioSystems Co-Founder , Executive Chairman & Chief Scientific Officer 000 0000
Gareth Asten Acre Venture Partners Board Member 000 0000
Patrick Zhang Horizons Ventures Board Member 000 0000
Roger Wyse Ph.D Spruce Capital Partners Board Member 000 0000
Simon Barnes Ph.D Tate & Lyle Ventures Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Evolve BioSystems Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evolve BioSystems Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Arla Foods Corporation Minority 000 0000 000000 0
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
Continental Grain Company Corporation Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Acre Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »